scholarly journals Correction: Evaluation of Changes in Morphology and Function of Human Induced Pluripotent Stem Cell Derived Cardiomyocytes (HiPSC-CMs) Cultured on an Aligned-Nanofiber Cardiac Patch

PLoS ONE ◽  
2015 ◽  
Vol 10 (10) ◽  
pp. e0141176 ◽  
Author(s):  
Mahmood Khan ◽  
Yanyi Xu ◽  
Serena Hua ◽  
Jed Johnson ◽  
Andriy Belevych ◽  
...  
2016 ◽  
Vol 119 (suppl_1) ◽  
Author(s):  
Jordan J Lancaster ◽  
Ike Chinyere ◽  
Bin Na Kim ◽  
Sherry Daugherty ◽  
Samuel Kim ◽  
...  

Introduction: Previously we have demonstrated that a tissue engineered heart patch comprised of human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) and fibroblasts improves both left ventricular (LV) systolic and diastolic function in a rat model of CHF. In this study we tested the feasibility of upscaling cardiac patch size and surgical deployment in a swine model of CHF to test clinical utility. Methods: Four male Gottingen mini swine 20-25kg and three domestic swine 50-60kg were infarcted using percutaneous methods. Embolizing coils were deployed via catheter distal to the first diagonal branch of the left anterior descending (LAD) coronary artery and animals recovered for 4 weeks. Cardiac patches engineered with bio absorbable polygalactin-910 knitted mesh, dermal fibroblasts and hiPSC-CMs were cultured and implanted on the infarcted epicardium 4 weeks after MI. Cardiac magnetic resonance imaging was performed at baseline, 4 and 8 weeks post MI. All swine were implanted with continuous event recorders to acquire surface electrocardiogram during the entire study. In addition quality of life and functional capacity were assessed through video monitoring and treadmill exertion testing respectively. Infarct size was determined through 2,3,5-triphenyltetrazolium chloride staining. Results: LAD occlusion resulted in a significant (P<0.05) decrease EF (15%), and increase in EDV (59%) and ESV (100%). Average TIMI score decreased from 3.0±0 at time of MI to 1.5±0.6 4wks post MI. Cardiac patches were upsized to 6cm diameter for application in the swine. Patches displayed synchronous and spontaneous contractions within 48hrs. The 6cm patches, when implanted effectively covered the infarcted region bridging viable myocardium. Surgical handling and epicardial deployment was successfully accomplished via median sternotomy. The patches were robust in nature and could be deployed via a minimally invasive robotic procedure. No adverse arrhythmic activity was observed. Implantation of the cardiac patch restored activity levels (quality of life) of patch treated swine vs CHF controls. Conclusion: Our hiPSC-CM cardiac patch can be constructed in a clinical size, easily handled and implanted on the epicardium of the infarcted heart.


2018 ◽  
Vol 123 (Suppl_1) ◽  
Author(s):  
Alexa Wnorowski ◽  
Arun Sharma ◽  
Haodong Chen ◽  
Haodi Wu ◽  
Ning-Yi Shao ◽  
...  

Immunity ◽  
2020 ◽  
Vol 52 (2) ◽  
pp. 417-418
Author(s):  
Kazuyuki Takata ◽  
Tatsuya Kozaki ◽  
Christopher Zhe Wei Lee ◽  
Morgane Sonia Thion ◽  
Masayuki Otsuka ◽  
...  

2019 ◽  
Vol 13 (6) ◽  
pp. 960-969 ◽  
Author(s):  
Alexa Wnorowski ◽  
Arun Sharma ◽  
Haodong Chen ◽  
Haodi Wu ◽  
Ning-Yi Shao ◽  
...  

Author(s):  
Claudia Coronnello ◽  
Maria Giovanna Francipane

AbstractThe advent of induced pluripotent stem cell (iPSC) technology, which allows to transform one cell type into another, holds the promise to produce therapeutic cells and organs on demand. Realization of this objective is contingent on the ability to demonstrate quality and safety of the cellular product for its intended use. Bottlenecks and backlogs to the clinical use of iPSCs have been fully outlined and a need has emerged for safer and standardized protocols to trigger cell reprogramming and functional differentiation. Amidst great challenges, in particular associated with lengthy culture time and laborious cell characterization, a demand for faster and more accurate methods for the validation of cell identity and function at different stages of the iPSC manufacturing process has risen. Artificial intelligence-based methods are proving helpful for these complex tasks and might revolutionize the way iPSCs are managed to create surrogate cells and organs. Here, we briefly review recent progress in artificial intelligence approaches for evaluation of iPSCs and their derivatives in experimental studies. Graphical Abstract


Immunity ◽  
2017 ◽  
Vol 47 (1) ◽  
pp. 183-198.e6 ◽  
Author(s):  
Kazuyuki Takata ◽  
Tatsuya Kozaki ◽  
Christopher Zhe Wei Lee ◽  
Morgane Sonia Thion ◽  
Masayuki Otsuka ◽  
...  

2019 ◽  
Author(s):  
Heyne Lee ◽  
Rowan Flynn ◽  
Ishta Sharma ◽  
Phillippa J. Carling ◽  
Francesca J. Nicholls ◽  
...  

SummaryThe Parkinson’s disease-associated gene, LRRK2, is also associated with immune disorders and infectious disease, and is expressed in immune subsets. Here, we characterise a platform for interrogating the expression and function of endogenous LRRK2 in authentic human phagocytes, using human induced Pluripotent Stem Cell-derived macrophages and microglia. Endogenous LRRK2 is expressed and upregulated by interferon-γ in these cells, including a 187kD cleavage product. Using LRRK2 knockout and G2019S isogenic repair lines, we find that LRRK2 is not involved in initial phagocytic uptake of bioparticles, but is recruited to LAMP1(+)/Rab9(+) ‘maturing’ phagosomes, and LRRK2 kinase inhibition enhances its residency at the phagosome. Importantly, LRRK2 is required for Rab8a and Rab10 recruitment to phagosomes, implying that LRRK2 operates at the intersection between phagosome maturation and recycling pathways in these professional phagocytes.


Sign in / Sign up

Export Citation Format

Share Document